Key clinical point: Clinical utility of NGS testing of tumor samples appears to be low.
Major finding: A change in management occurred with just 11.1% of usable tests, 8.3% of completed tests, and 6.9% of all ordered tests.
Study details: Single-center retrospective cohort study of 305 consecutive patients for whom NGS testing was ordered during 2014-2017.
Disclosures: Dr. Kubicek disclosed no relevant conflicts of interest. The study did not receive any specific funding.
Davis W et al. J Oncol Pract. 2019 Aug 2. doi: 10.1200/JOP.19.00269.